Prevalence of HIV-AssociatedMetabolic Abnormalities among Patients Taking First-Line Antiretroviral Therapy in Uganda

Simple item page
dc.contributor.authorOmech, Bernard
dc.contributor.authorSempa, Joseph
dc.contributor.authorCastelnuovo, Barbara
dc.contributor.authorOpio, Kenneth
dc.contributor.authorOtim, Marcel
dc.contributor.authorMayanja-Kizza, Harriet
dc.contributor.authorColebunders, Robert
dc.contributor.authorManabe, Yukari C.
dc.date.accessioned2021-11-22T12:11:53Z
dc.date.available2021-11-22T12:11:53Z
dc.date.issued2012
dc.description.abstractIntroduction. While the introduction of highly active antiretroviral therapy decreased HIV-related morbidity and mortality rates in the sub-Saharan Africa, a subsequent increase in metabolic abnormalities has been observed. We sought to determine the prevalence of HIV-associated metabolic abnormalities among patients on first-line antiretroviral therapy (ART) in an ART clinic in Kampala, Uganda. Methods. Four hundred forty-two consecutive patients on first-line ART for at least 12 months were screened for eligibility in a cross-sectional study, and 423 were enrolled. Pre-ART patient characteristics were abstracted from medical charts, examinations included anthropometric measurement and physical assessment for lipodystrophy. Results. The prevalence of hyperglycemia and dyslipidemia was 16.3% (69/423) and 81.5% (345/423), respectively. Prevalence of dyslipidemia between stavudine- and zidovudine-based regimens (91% versus 72%; P < 0.001). Being on stavudine (aOR 4.79, 95%, 2.45–9.38) and peak body weight (aOR 1.44, 95% CI 1.05–1.97) were independent risk factors for dylipidemia. Stavudine (aOR 0.50, 95% CI 0.27–0.93) use was associated with lower risk for hyperglycemia while, and older age (aOR 1.31, 95% CI 1.11–1.56) and having a family history of DM (aOR 2.18, 95% CI 1.10–4.34) were independent risk factors for hyperglycemia. Conclusions. HIV-associated metabolic complications were prevalent among patients on thymidine analogue-containing ART regimens. Screening for lipid and glucose abnormalities should be considered in ART patients because of cardiovascular risks.en_US
dc.identifier.citationOmech, B., Sempa, J., Castelnuovo, B., Opio, K., Otim, M., Mayanja-Kizza, H., ... & Manabe, Y. C. (2012). Prevalence of HIV-associated metabolic abnormalities among patients taking first-line antiretroviral therapy in Uganda. International Scholarly Research Notices, 2012.en_US
dc.identifier.urihttps://hdl.handle.net/123456789/348
dc.language.isoenen_US
dc.publisherInternational Scholarly Research Networken_US
dc.subjectAntiretroviralen_US
dc.subjectMetabolic Abnormalitiesen_US
dc.subjectUgandaen_US
dc.titlePrevalence of HIV-AssociatedMetabolic Abnormalities among Patients Taking First-Line Antiretroviral Therapy in Ugandaen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Prevalence of HIV-AssociatedMetabolic.pdf
Size:
1.16 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Articles